Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Icu Medical Inc (ICUI)
Price$165.87Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B | $1.27B | $1.27B | $1.40B | $1.29B | $379.4M | $341.7M | $309.3M | $313.7M | $316.9M | $302.2M | $283.0M | $229.0M | $204.7M | $188.1M |
| Gross profit | $822.0M | $824.8M | $739.9M | $697.8M | $491.5M | $461.5M | $471.9M | $570.0M | $426.1M | $201.4M | $180.8M | $151.4M | $154.7M | $156.5M | $142.4M | $129.0M | $106.3M | $89.8M | $78.2M |
| Gross margin | 36.84% | 34.62% | 32.75% | 30.60% | 37.34% | 36.31% | 37.27% | 40.72% | 32.96% | 53.09% | 52.92% | 48.96% | 49.32% | 49.39% | 47.11% | 45.58% | 46.41% | 43.87% | 41.59% |
| Research & development | $87.5M | $88.6M | $85.3M | $93.0M | $47.5M | $42.9M | $48.6M | $52.9M | $51.3M | $13.0M | $15.7M | $18.3M | $12.4M | $10.6M | $8.6M | $4.7M | $2.6M | $4.8M | $8.1M |
| Operating expenses | $779.2M | $781.8M | $717.0M | $740.7M | $368.2M | $363.3M | $364.5M | $540.3M | $439.4M | $118.5M | $112.2M | $112.4M | $102.8M | $95.2M | $77.1M | $81.3M | $70.8M | $58.4M | $53.6M |
| Operating income | $42.8M | $43.0M | $22.8M | −$42.9M | $123.2M | $98.2M | $107.4M | $29.8M | −$13.3M | $82.9M | $68.6M | $39.0M | $51.9M | $61.3M | $65.2M | $47.7M | $35.4M | $31.4M | $24.6M |
| Operating margin | 1.92% | 1.80% | 1.01% | −1.88% | 9.36% | 7.72% | 8.48% | 2.13% | −1.03% | 21.86% | 20.07% | 12.62% | 16.56% | 19.34% | 21.58% | 16.84% | 15.47% | 15.33% | 13.10% |
| EBITDA | $243.6M | $262.5M | $251.6M | $192.3M | $212.9M | $183.8M | $184.3M | $104.5M | $53.3M | $102.0M | $86.6M | $58.5M | $71.5M | $80.3M | $83.5M | $65.0M | $51.1M | $45.6M | $36.4M |
| EBITDA margin | 10.92% | 11.02% | 11.14% | 8.43% | 16.18% | 14.46% | 14.55% | 7.46% | 4.12% | 26.88% | 25.36% | 18.91% | 22.78% | 25.33% | 27.64% | 22.97% | 22.32% | 22.28% | 19.37% |
| Net income | $732,000 | −$117.7M | −$29.7M | −$74.3M | $103.1M | $86.9M | $101.0M | $28.8M | $68.6M | $63.1M | $45.0M | $26.3M | $40.4M | $41.3M | $44.7M | $29.9M | $25.0M | $24.3M | $23.1M |
| Net profit margin | 0.03% | −4.94% | −1.31% | −3.26% | 7.84% | 6.83% | 7.98% | 2.06% | 5.31% | 16.63% | 13.17% | 8.52% | 12.88% | 13.03% | 14.78% | 10.58% | 10.91% | 11.87% | 12.27% |
| Basic EPSper basic share | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.86 | $4.16 | $4.90 | $1.41 | $3.50 | $3.90 | $2.84 | $1.72 | $2.75 | $2.90 | $3.23 | $2.20 | $1.70 | $1.72 | $1.62 |
| Diluted EPSper diluted share | $0.03 | -$4.83 | -$1.23 | -$3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 | $2.73 | $1.68 | $2.65 | $2.80 | $3.15 | $2.16 | $1.67 | $1.67 | $1.51 |
Owners
Reported shareholders
15.01%of listed shares
BlackRock, Inc.3.75M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 15.01%3.75M shares |
Jupiter Topco LLC | 11.12%2.78M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.88%1.47M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 5.19%1.3M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.49%1.12M shares |
DIMENSIONAL FUND ADVISORS LP | 4.21%1.05M shares |
STATE STREET CORP | 4.10%1.02M shares |
SCHRODER INVESTMENT MANAGEMENT GROUP | 2.96%739.14K shares |
AMERIPRISE FINANCIAL INC | 2.76%689.57K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.64%660.42K shares |
River Road Asset Management, LLC | 2.50%626.29K shares |
CITADEL ADVISORS LLC | 2.14%536.23K shares |
NEUBERGER BERMAN GROUP LLC | 1.80%451.28K shares |
JPMORGAN CHASE & CO | 1.76%440.47K shares |
GOLDMAN SACHS GROUP INC | 1.67%417.34K shares |
Thrivent Financial for Lutherans | 1.52%381.14K shares |
MORGAN STANLEY | 1.49%372.58K shares |
BANK OF AMERICA CORP /DE/ | 1.47%368.75K shares |
TORONTO DOMINION BANK | 1.43%358.02K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.32%331.05K shares |
Percentages use 25.01M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 22, 2026Form 4 | Woolson DanielPresident | SellCommon Stock | 2.1K | $132.21 | $280.7K | 22.5K |
| May 14, 2026Form 4 | Sanzone Virginia RuthVP, General Counsel | SellCommon Stock | 2.4K | $124.08 | $303.6K | 19.5K |
| May 12, 2026Form 4 | Greenberg David C.Director | SellCommon Stock | 2.4K | $122.91 | $297.9K | 8.0K |
| Nov 25, 2025Form 4 | Woolson DanielVP, GM-Infusion Capital | SellCommon Stock | 2.9K | $152.35 | $441.4K | 11.3K |
| Nov 11, 2025Form 4 | Sanzone Virginia RuthVP, General Counsel | SellCommon Stock | 930 | $142.35 | $132.4K | 5.5K |